BioCentury
ARTICLE | Clinical News

AERx nicotine: Phase I data

October 29, 2007 7:00 AM UTC

In an open-label Phase I trial in 18 adult smokers, single 0.2, 0.4 and 0.7 mg doses of AERx nicotine were well tolerated. In the low-, medium- and high-dose groups, mean craving scores were reduced t...